Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)

The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding nelfinavir to lenalidomide–dexamethasone can overcome lenalidomide resistance in lenalidomide-refractory multiple myeloma (MM). Twenty-nine patient...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Cancer J
Main Authors: Hitz, F., Kraus, M., Pabst, T., Hess, D., Besse, L., Silzle, T., Novak, U., Seipel, K., Rondeau, S., Stüdeli, S., Vilei, S. Berardi, Samaras, P., Mey, U., Driessen, C.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6711992/
https://ncbi.nlm.nih.gov/pubmed/31455773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0228-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker